Loading...

ETON ETON PHARMACEUTICALS INC Company Mergers 8-K Filing

TN P

TN

ETON PHARMACEUTICALS INC

(ETON)

2026 8-K

New Agreement Signed

Financial Results Announced

Product Study Announcement

Management Change

Credit Agreement Amendment

Financial Results Report

Licensing Agreement

FDA Approval Granted

New Product Licensing

Management Conference

Increlex Acquisition

Quarterly Results

Financial Statements

New Product Launches

New Product Launches

Financial Statements

Asset Acquisitions

Product Expansion

Licensing Agreement

Financial Results

Positive Study Results

Increlex Acquisition

FDA Review Extension

Asset Acquisition

Asset Acquisition

Clinical Trial Results

Management Change

Licensing Agreement

Q3 Financial Results

Asset Acquisition

Financial Results Announcement

Shareholder Advisory Votes ...

Acceptance of NDA for hydro...

Accounting Firm Change

Annual Meeting of Stockholders

Financial Results Announcement

Submission of NDA for hydro...

Investments Cancelled

Acquisition Agreement

Financial Results Announcement

Financial Results Announcement

Acquisition of Drug Applica...

Earnings Report

Acquisition Agreement and A...

Annual Meeting Results

Earnings Reports

Earnings Reports

Regulation FD Disclosure

Appointment of Chief Busine...

FDA Accepts NDA Response fo...

External Links:

Eton Pharmaceuticals has entered into a supply and distribution agreement with Knight Therapeutics on May 18, 2026, for the commercialization rights to IMPAVIDO® (miltefosine) in the U.S., agreeing to pay $4.25 million over several years, and a percentage of sales exceeding certain thresholds.

AI Assistant

ETON PHARMACEUTICALS INC

2026

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.